Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 11;71(1):19.
doi: 10.1007/s00005-023-00684-x.

Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer

Yu Cao  1 , Sergey K Efetov  1 , Mingze He  1 , Yu Fu  1 , Narasimha M Beeraka  1   2 , Jin Zhang  1 , Xinliang Zhang  1 , Namitha Bannimath  3 , Kuo Chen  4
Affiliations
Free article
Review

Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer

Yu Cao et al. Arch Immunol Ther Exp (Warsz). .
Free article

Abstract

In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has increased worldwide and caused a higher mortality rate due to the lack of selective anti-tumor therapies. Current chemotherapies and surgical interventions are significantly preferred modalities to treat CRC or BC in advanced stages but the prognosis for patients with advanced CRC and BC remains dismal. The immunotherapy technique of chimeric antigen receptor (CAR)-T cells has resulted in significant clinical outcomes when treating hematologic malignancies. The novel CAR-T therapy target antigens include GUCY2C, CLEC14A, CD26, TEM8/ANTXR1, PDPN, PTK7, PODXL, CD44, CD19, CD20, CD22, BCMA, GD2, Mesothelin, TAG-72, CEA, EGFR, B7H3, HER2, IL13Ra2, MUC1, EpCAM, PSMA, PSCA, NKG2D. The significant aim of this review is to explore the recently updated information pertinent to several novel targets of CAR-T for CRC, and BC. We vividly described the challenges of CAR-T therapies when treating CRC or BC. The immunosuppressive microenvironment of solid tumors, the shortage of tumor-specific antigens, and post-treatment side effects are the major hindrances to promoting the development of CAR-T cells. Several clinical trials related to CAR-T immunotherapy against CRC or BC have already been in progress. This review benefits academicians, clinicians, and clinical oncologists to explore more about the novel CAR-T targets and overcome the challenges during this therapy.

Keywords: Breast cancer; CAR-T; Challenges; Colorectal cancer; Immunotherapy; Novel CAR-T targets; Solid tumor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahn JC, Teng PC, Chen PJ et al (2021) Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology 73:422–436. https://doi.org/10.1002/hep.31165 - DOI - PubMed
    1. Amatya C, Pegues MA, Lam N et al (2021) Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7. Mol Ther 29:702–717. https://doi.org/10.1016/j.ymthe.2020.10.008 - DOI - PubMed
    1. Aoe T, Goto S, Ohno H et al (1994) Different cytoplasmic structure of the CD3ζ family dimer modulates the activation signal and function of T cells. Int Immunol 6:1671–1679. https://doi.org/10.1093/intimm/6.11.1671 - DOI - PubMed
    1. Baybutt T, Snook A, Waldman S et al (2020) 105 A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy. J Immunother Cancer 8(Suppl 3):A116–A116. https://doi.org/10.1136/jitc-2020-SITC2020.0105 - DOI
    1. Boice M, Salloum D, Mourcin F et al (2016) Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell 167:405–418. https://doi.org/10.1016/j.cell.2016.08.032 - DOI - PubMed - PMC